CCO Independent Conference Coverage: Clinical Impact of New Data From EASL 2021

June 23-26, 2021; Virtual
In this downloadable slideset, CCO’s expert faculty members summarize key viral hepatitis studies from this important conference, including new data on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure.
Tarik Asselah, MD, PhD
Robert G. Gish, MD
Nancy Reau, MD
Stefan Zeuzem, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 754 KB
Released: July 15, 2021

Acknowledgements

Educational grant provided by:
AbbVie
Antios Therapeutics
Gilead Sciences, Inc.

Related Content

Dr Graham Foster on optimizing management of HBV in older adults, from Clinical Care Options (CCO)

Graham R. Foster, FRCP, PhD Released: January 17, 2023

Expert analysis by Dr Nancy Reau on new viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 8, 2022

Clinical Care Options (CCO) expert analysis by Dr Stefan Zeuzem on new viral hepatitis data from AASLD 2022

Stefan Zeuzem, MD Released: December 7, 2022

Dr Nancy Reau: practice-changing viral hepatitis data from AASLD 2022, from Clinical Care Options (CCO)

Nancy Reau, MD Released: December 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings